PainReform to Participate at M Vest LLC and Maxim Group LLC Inaugural Emerging Growth Virtual Conference

Rhea-AI Summary

PainReform Ltd. (Nasdaq: PRFX) announced that CEO Ilan Hadar will present at the Inaugural Emerging Growth Virtual Conference from March 17-19, 2021. This presentation will be accessible to registered participants and later posted on PainReform’s website. The company specializes in reformulating established therapeutics, with its lead product, PRF-110, focusing on post-operative pain relief using a local anesthetic, ropivacaine. PRF-110 aims to provide extended analgesia through a unique delivery system, reducing the need for opiates.

HERZLIYA, Israel, March 11, 2021 (GLOBE NEWSWIRE) -- PainReform Ltd. (Nasdaq: PRFX) (“PainReform” or the “Company”), a clinical stage specialty pharmaceutical company focused on the reformulation of established therapeutics, today announced that Ilan Hadar, CEO of PainReform, has been invited to present at the Inaugural Emerging Growth Virtual Conference, hosted by M Vest LLC and Maxim Group LLC. The presentation will be available to all registered participants of the conference on March 17^th - 19^th and will be posted on PainReform’s website after March 19^th.

About PainReform

PainReform is a clinical stage specialty pharmaceutical company focused on the reformulation of established therapeutics. PRF-110, the Company’s lead product, is based on the local anesthetic ropivacaine, targeting the post-operative pain relief market. PRF-110 is an oil-based, viscous, clear solution that is deposited directly into the surgical wound bed prior to closure to provide localized and extended post-operative analgesia. The Company’s proprietary extended-release drug-delivery system is designed to provide an extended period of post-surgical pain relief without the need for repeated dose administration while reducing the potential need for the use of opiates.

Contact:

Crescendo Communications, LLC

Tel: 212-671-1021

Email: prfx@crescendo-ir.com

FAQ

When will PainReform's CEO present at the Emerging Growth Virtual Conference?

Ilan Hadar, CEO of PainReform, will present at the Emerging Growth Virtual Conference from March 17-19, 2021.

What is PainReform's lead product and its purpose?

PainReform's lead product, PRF-110, is designed for extended post-operative pain relief by utilizing the local anesthetic ropivacaine.

How can I access PainReform's conference presentation?

The presentation will be available to registered participants during the conference and will be posted on PainReform’s website after March 19, 2021.

What is the main focus of PainReform Ltd.?

PainReform Ltd. focuses on the reformulation of established therapeutics to improve pain management.

How does PRF-110 provide pain relief?

PRF-110 provides localized and extended pain relief by being deposited directly into the surgical wound bed prior to closure.